Peak Values of Lipid and Lipoprotein by Timepoint of Asparaginase Therapy for Patients With Complete Serial Data
| . | N . | Mean (SD) . | ||
|---|---|---|---|---|
| . | . | Pre . | During . | Post . |
| Triglyceride*†‡ | 21 | 108 (46) | 465 (492) | 73 (33) |
| Cholesterol3-151 | 21 | 172 (40) | 205 (73) | 161 (41) |
| LDL | 20 | 121 (33) | 97 (49) | 97 (29) |
| HDL*† | 21 | 36 (13) | 37 (15) | 46 (11) |
| Apo-A1 | 7 | 133 (33) | 124 (36) | 128 (28) |
| Apo-B100†‡ | 7 | 122 (31) | 176 (115) | 78 (26) |
| . | N . | Mean (SD) . | ||
|---|---|---|---|---|
| . | . | Pre . | During . | Post . |
| Triglyceride*†‡ | 21 | 108 (46) | 465 (492) | 73 (33) |
| Cholesterol3-151 | 21 | 172 (40) | 205 (73) | 161 (41) |
| LDL | 20 | 121 (33) | 97 (49) | 97 (29) |
| HDL*† | 21 | 36 (13) | 37 (15) | 46 (11) |
| Apo-A1 | 7 | 133 (33) | 124 (36) | 128 (28) |
| Apo-B100†‡ | 7 | 122 (31) | 176 (115) | 78 (26) |
All values expressed in milligrams per deciliter. Significant differences noted at P < .05.
Abbreviations: Pre, before initiation of asparaginase; During, during 30-week asparaginase therapy; Post, after completion of asparaginase therapy.
Significant difference between Pre and During levels.
Significant difference between During and Post levels.
Significant difference between Pre and Post levels.